Prelude Therapeutics (PRLD) Net Margin (2024 - 2026)

Prelude Therapeutics has reported Net Margin for 3 years, with the latest figure at 752.05% in Q1 2026.

• Quarterly Net Margin changed N/A year-over-year to 752.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 891.23% (changed N/A YoY) and the FY2025 annual result came in at 2606.84%, up 199825.0% from the prior year.
• Net Margin fell to 752.05% in Q1 2026 per PRLD's latest filing, from 320.6% in the prior quarter.
• Over five years, Net Margin peaked at 320.6% in Q4 2025 and troughed at 2549.4% in Q3 2024.
• A 3-year average of 1025.52% and a median of 752.05% in 2026 frame the typical range for Net Margin.
• The widest YoY moves for Net Margin: up 190294 bps in 2025, down 53847 bps in 2025.
• Over 3 years, Net Margin stood at 859.08% in 2024, then surged by 63 bps to 320.6% in 2025, then tumbled by 135 bps to 752.05% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 752.05%, 320.6%, and 646.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.